Clinical Trials Sponsored by Celularity Incorporated

Total 1167 results

Celularity Incorporated

Recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With AML (CYNK001AML01)

Neoplasms | Neoplasms by Histologic Type | Hematologic Diseases | Leukemia | Leukemia, Myeloid | Leukemia, Myeloid, Acute | Hematologic Neoplasms | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Antimetabolites, Antineoplastic | Leukemia in Remission | Relapsed... and other conditions

United States
Celularity Incorporated

Terminated

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM (CYNK001GBM01)

Glioblastoma Multiforme | Molecular Mechanisms of Pharmacological Action | Giant Cell Glioblastoma | Astrocytoma, Grade IV | Physiological Effects of Drugs | Peripheral Nervous System Agents | Analgesics | Analgesics, Non-narcotic | Cyclophosphamide | Immunosuppressive Agents | Immunologic Factors | Antiviral... and other conditions

United States
Celularity Incorporated

Terminated

Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
Celularity Incorporated

Active, not recruiting

CYNK-101 in Combination With Trastuzumab and Pembrolizumab in Patients With Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Metastatic HER2 Positive Gastroesophageal Junction Cancer

United States
Celularity Incorporated

Completed

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Multiple Myeloma

United States
Celularity Incorporated

Completed

A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Crohns Disease

United States
Celularity Incorporated

Terminated

Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

Stage 2 Pulmonary Sarcoidosis | Stage 3 Pulmonary Sarcoidosis

United States
Celularity Incorporated

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemorrhagic Disorders | Multiple Myeloma | Paraproteinemias | Blood Protein Disorders | Antineoplastic Agents | Physiological... and other conditions

United States
Celularity Incorporated

Withdrawn

CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type (CYNK001GBM02)

Glioblastoma | Glioblastoma Multiforme | Giant Cell Glioblastoma | Astrocytoma, Grade IV

United States
Celularity Incorporated

Completed

A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Peripheral Nervous System Diseases | Diabetic Nephropathies

United States
Celularity Incorporated

Terminated

A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Leukemia, Myeloid, Acute

United States
Celularity Incorporated

Withdrawn

Safety, Hemodynamic Effects and Efficacy of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
Celularity Incorporated

Completed

Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Diabetic Foot | Peripheral Arterial Disease

United States
Celularity Incorporated
Celgene Corporation

Terminated

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke

Stroke, Acute | Middle Cerebral Artery Stroke | Posterior Cerebral Artery Stroke

United States
Celularity Incorporated
Celgene Corporation

Terminated

Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

United States
Celularity Incorporated
Celgene Corporation

Completed

A Multi-Center Study to Evaluate the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Moderate-to-Severe Crohn's Disease

Crohn's Disease

United States
Celularity Incorporated
Lung Biotechnology PBC; California Institute for Regenerative Medicine (CIRM); ID...

Active, not recruiting

Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19 (CYNKCOVID)

Coronaviridae Infections | Nidovirales Infections | RNA Virus Infections | Respiratory Tract Infections | Coronavirus Infection | Pneumonia, Viral | Pneumonia | Lung Diseases | ARDS | Coronavirus | Severe Acute Respiratory Syndrome Coronavirus 2 | Respiratory Tract Disease | Virus Disease | Physiological Effects of... and other conditions

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Inguinal Hernia Study Using Biodesign IHM

Inguinal Hernia

United States
Cook Group Incorporated
MED Institute, Incorporated; Cook Biotech Incorporated

Completed

Evaluation of Surgisis Gold Graft for Incision Reinforcement After Open Bariatric Surgery

Obesity | Hernia

United States
Cook Research Incorporated

Recruiting

Post Market Clinical Study - Evolution® Esophageal Stent Systems, Europe: Fully and Partially Covered

Esophageal Diseases

Germany, Spain, United Kingdom
Cook Research Incorporated

Recruiting

Zenith® Fenestrated+ Clinical Study

Aortic Aneurysm, Abdominal | Juxtarenal Aortic Aneurysm | Extent IV Thoracoabdominal | Pararenal Aneurysm

United States
Cook Research Incorporated

Recruiting

Biodesign® Otologic Repair Graft

Tympanic Membrane Perforation | Eardrum Perforation

United States
Cook Research Incorporated

Completed

Comparing a Direct Versus an Indirect Approach to Measuring the Portalsytemic Pressure Gradients

Liver Cirrhosis

Belgium, Spain, Netherlands
Cook Research Incorporated

Completed

Zenith® p-Branch® and Zenith® Fenestrated AAA Endovascular Graft Clinical Study (FENP)

Aortic Aneurysm, Abdominal

United States
Cook Research Incorporated

Completed

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Measurements

Liver Diseases | Liver Cirrhosis | Hypertension, Portal

United States, Australia, Hong Kong
Cook Research Incorporated

Completed

Zilver® PTX® V Clinical Study

Peripheral Arterial Disease

United States
Cook Research Incorporated

Completed

Zenith TX2® Post-market Approval Study (TX2 2PAS)

Descending Thoracic Aortic Aneurysm

United States, Canada
Cook Research Incorporated

Completed

Zenith® Dissection Clinical Trial

Aortic Dissection

United States, Japan
Cook Research Incorporated

Terminated

HemaTrate™ in the Treatment of Critical Limb Ischemia

Ischemia | Critical Limb Ischemia

United Kingdom
Cook Research Incorporated

Completed

Cook Enforcer Post-Market Study

End-Stage Renal Disease

United States
Cook Group Incorporated
Cook Biotech Incorporated

Terminated

Treatment of Crohn's Fistula Using a Porcine Intestine Submucosa Graft (SurgiSIS AFP)

Crohn's Disease | Anal Fistula

United States
Insmed Incorporated

Recruiting

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Argentina, Australia, Belgium, Brazil, Germany, Italy, Japan, Malaysia, Mexico, Philippines, Switzerland, United Kingdom, Serbia, Austria, Denmark
Insmed Incorporated

Active, not recruiting

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis (ASPEN)

Non-Cystic Fibrosis Bronchiectasis

New Zealand, United States, Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, Chile, Colombia, Denmark, France, Germany, Greece, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic of, Latvia, Malaysia, Mexico, Nethe... and more
Insmed Incorporated

Available

An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis
Insmed Incorporated

Completed

A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy Participants

Healthy Volunteers

United States
Insmed Incorporated

Completed

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis

Cystic Fibrosis

United States
Insmed Incorporated

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy Participants

Healthy Volunteers

United States
Lenstec Incorporated

Completed

Clinical Evaluation of the Lenstec SBL-3 Multifocal Intraocular Lens

Presbyopia | Cataracts

United States
Insmed Incorporated

Completed

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Non-Cystic Fibrosis Bronchiectasis

United States, Spain, Korea, Republic of, Australia, Denmark, United Kingdom, Italy, Belgium, Singapore, Bulgaria, Germany, Netherlands, New Zealand, Poland
Insmed Incorporated

Completed

A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male Participants

Healthy Volunteers

United States
GlycoMimetics Incorporated

Terminated

Safety of Rivipansel (GMI-1070) in the Treatment of One or More Vaso-Occlusive Crises in Hospitalized Subjects With Sickle Cell Disease

Sickle Cell Disease | Sickle Cell Anemia | Vaso-occlusive Crisis | Pain Crisis | Sickle Cell Disorders

United States, Canada
VertiFlex, Incorporated

Completed

The STEPS - Totalis™ Trial

Lumbar Spinal Stenosis

United States
GlycoMimetics Incorporated

Completed

A Study to Evaluate the Effect of Age on the Pharmacokinetics, Safety and Tolerability of IV Rivipansel.

Healthy

United States
GlycoMimetics Incorporated

Completed

Study of Intravenous GMI-1070 in Adults With Sickle Cell Disease

Sickle Cell Disease

United States
VertiFlex, Incorporated

Withdrawn

Assessing Superion Clinical Endpoints vs. Decompression (ASCEND)

Spinal Stenosis, Lumbar Region With Neurogenic Claudication

United States
GlycoMimetics Incorporated

Completed

Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML

Leukemia, Myeloid, Acute

United States, Ireland, Australia
Hollister Incorporated

Completed

The Advocate Study

Ostomy

United States, Canada
Hollister Incorporated

Completed

Wound Fluid Protease Levels During Use of Novel Wound Dressing

Venous Stasis Ulcers

United States
Ingredion Incorporated

Completed

Effects of Dietary Fiber on Gastrointestinal Function

Gastrointestinal Health

United States

Clinical Trials Sponsored by Celularity Incorporated

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations